Ethinylestradio-Chlormadinone Acetate Combination for the Treatment of Hirsutism and Hormonal Alterations of Normal-Weight Women With Polycystic Ovary Syndrome: Evaluation of the Metabolic Impact
Restricted accessResearch articleFirst published online August, 2010
Ethinylestradio-Chlormadinone Acetate Combination for the Treatment of Hirsutism and Hormonal Alterations of Normal-Weight Women With Polycystic Ovary Syndrome: Evaluation of the Metabolic Impact
This is the first study evaluating the clinical, metabolic, and hormonal effects of the ethinylestradiol—chlormadinone acetate (EECMA) combination in hirsute women with polycystic ovary syndrome (PCOS). Ultrasonographic pelvic examination, hirsutism score, and hormone profile evaluation were performed at baseline and after 3 and 6 cycles of treatment. Oral glucose tolerance test, euglycemic—hyperinsulinemic clamp, and assessment of lipid profile were carried out at baseline and after 6 cycles of treatment. A significant improvement in hirsutism was evident at the end of treatment. From the third cycle onward, plasma levels of sex hormone binding globulin significantly increased when compared to baseline. Free androgen index, androstenedione, and 17-hydroxyprogesterone significantly decreased after 6 cycles. The treatment did not affect glucose and insulin homeostasis. Total cholesterol, triglycerides, and high-density lipoprotein (HDL) plasma levels remained unvaried, whereas low-density lipoprotein (LDL) concentrations showed a significant reduction. A significant increase in very-low-density lipoprotein (VLDL) levels was seen at the sixth cycle of therapy. In conclusion, EE-CMA combination ameliorates clinical and hormonal features of PCOS women, with no detrimental effects on glucose, insulin, and lipid metabolism.
Franks S.Polycystic ovary syndrome. New Engl J Med.1995;333(13):853-861.
2.
Falsetti L., Galbignani E.Long term treatment with the combination ethinyl-estradiol and cyproterone acetate in polycystic ovary syndrome. Contraception. 1990;42(6):611-619.
3.
Olympia K., Gerard S.Conway. A systemic review of commonly used medical treatments for hirsutism in women. Clin Endocrinol. 2008;68(5):800-805.
4.
Krysiak R., Okopieñ B., Gdula-Dymek A., Herman ZSUpdate on the management of polycystic ovary syndrome. Pharmacol Rep.2006;58(5):614-625.
5.
Warren-Ulanch J., Arslanian S.Treatment of PCOS in adolescence . Best Pract Res Clin Endocrinol Metabol. 2006;20(2): 311-330.
6.
Botwood N., Hamilton-Fairley D., Kiddy D., Robinson S., Franks S.Sex hormone-binding globulin and female reproductive function. J Steroid Biochem Mol Biol.1995;53(1-6):529-531.
7.
Toscano V., Balducci R., Bianchi P., Guglielmi R., Mangiantini A., Sciarra F.Steroidal and non-steroidal factors in plasma sex hormone binding globulin regulation. J Steroid Biochem Mol Biol. 1992 ;43(5):431-437.
8.
WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception.Acute myocardial infarction and combined oral contraceptives: results of international multicenter case-control study. Lancet. 1997;349(9060):1202-1209.
9.
Wild RALong-term health consequences of PCOS. Hum Reprod Update. 2002;8(3):231-241.
10.
Worret I., Arp W., Zahradnik HP, Zahradnik HP, Andreas JO, Binder N.Acne resolution rates: results of a single-blind, randomized, controlled, parallel phase III trial with EE/CMA (Belara) and EE/LNG (Microgynon). Dermatology. 2001;203(1):38-44.
11.
Schramm G., Steffens D.A 12-month evaluation of the CMAcontaining oral contraceptive Belara: efficacy, tolerability and anti-androgenic properties. Contraception . 2003;67(4):305-312.
12.
Heskamp ML, Schramm GAEfficacy of the low-dose combined oral contraceptive chlormadinone acetate/ethinylestradiol: physical and emotional benefits. Contraception.2010;81(1):49-56.
13.
Druckmann R.Profile of the progesterone derivative chlormadinone acetate-pharmocodynamic properties and therapeutic applications. Contraception. 2009;79(4):272-281.
14.
Bouchard P.Chlormadinone acetate (CMA) in oral contraception-a new opportunity. Eur J Contracept Reprod Health Care. 2005;10(suppl 1):7-11.
15.
Plewig G., Cunliffe WJ, Binder N., Höschen K.Efficacy of an oral contraceptive containing EE 0.03 mg and CMA 2 mg (Belara) in moderate acne resolution: a randomized, double-blind, placebo-controlled Phase III trial. Contraception.2009;80(1):25-33.
16.
Carranza-Lira S., Magaña-Padilla NRUltrasonographic and lipid changes in polycystic ovary syndrome according to the type of treatment . Ginecol Obstet Mex.2002;70(6):285-288.
17.
Carranza-Lira S., García-Hernández E., Baiza MR, Morán C.The relation of the gonadotrophin response to chlormadinone according to body weight in patients with amenorrhea due to polycystic ovarian syndrome. Eur J Obstet Gynecol Reprod Biol. 1996;66(2):161-164.
18.
Azziz R.Definition and epidemiology of the polycystic ovary syndrome Contemporary Endocrinology: Androgen Excess Disorders in Women: Polycystic Ovary Syndrome and Other Disorders, Second Edition, 2006.
19.
The Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod . 2004;19(1):41-47.
20.
Fulghesu AM , Ciampelli M., Belosi C., et al. A new ultrasound criterion for the diagnosis of polycystic ovary syndrome: the ovarian stroma/total area ratio . Fertil Steril. 2001;76(2):326-331.
21.
Van Hooff MH , Voorhorst FJ, et al. Endocrine features of polycystic ovary syndrome in a random population sample of 14-16 years old adolescents . Hum Reprod. 1999;14(9): 2223-2229.
22.
New MI, Lorenzen F., Lerner AJ, et al. Genotyping steroid 21-hydroxylase deficiency: hormonal reference data. J Clin Endocrinol Metab. 1983;57(2):320-326.
23.
Ferriman D. , Gallwey JDClinical assessment of body hair growth in women. J Clin Endocrinol Metab. 1961;21:1440-1447.
24.
Faber OK, Christensen K., Kehelet H., Madsbad S., Binder C.Decreased insulin removal contributes to hyperinsulinemic in obesity . J Clin Endocrinol Metab. 1981;53(3):618-621.
25.
De Fronzo JP , Tobin JD, Andrei R.Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol.1979;237(3):E214-E223.
26.
Bergman RN, Finegood DT, Ader M.Assessment of insulin sensitivity in vivo. Endocr Rev. 1985;6(1):45-86.
27.
Ciampelli M. , Fulghesu AM, Cucinelli F., et al. Impact of insulin and body mass index on metabolic and endocrine variables in polycystic ovary syndrome. Metabolism. 1999;48(2):167-172.
28.
Rivera R., Yacobson I., Grimes D.The mechanism of action of hormonal contraceptives and intrauterine contraceptive devices. Am J Obstet Gynecol.1999;181(5 Pt 1):1263-1269.
29.
Crook D., Godsland I.Safety evaluation of modern oral contraceptives. Effects on lipoprotein and carbohydrate metabolism. Contraception. 1998 ;57(3):189-201.
30.
De Pirro R. , Fusco A., Lauro R., et al. Insulin receptors on monocytes and erythrocytes from obese patients. J Clin Endocrinol Metab . 1980;51(6):1437-1439.
31.
Godsland IF , Walton C., Felton C., et al. Insulin resistance, secretion, and metabolism in users of oral contraceptives. J Clin Endocrinol Metab. 1992;74(1):64-70.
32.
Skouby SO, Endrikat J., Dusterberg B., et al. A 1-yr randomized study to evaluate the effects of a dose reduction in oral contraceptives on lipids and carbohydrate metabolism: 20 μg ethinyl estradiol combined with 100 μg levonorgesterel. Contraception . 2005;71(2):111-117.
33.
Lopez LM, Grimes DA, Schulz KFSteroidal contraceptives: effect on carbohydrate metabolism in women without diabetes mellitus. Cochrane Database Syst Rev.2007;(2):CD006133.
34.
Lüdicke F., Gaspard UJ, Demeyer F., Scheen A., Lefebvre P.Randomized controlled study of the influence of two low estrogen dose oral contraceptives containing gestodene or desogestrel on carbohydrate metabolism. Contraception. 2002;66(6):411-415.
35.
Polderman KH , Gooren LJG, Asscheman H., et al. Induction of insulin resistance by estrogens and androgens. J Clin Endocrinol Metab. 1994;79(1):265-271.
36.
Wild RA, Carmina E., Diamanti-Kandarakis E., Dokras A., et al. Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome (AE-PCOS) Society. J Clin Endocrinol Metab.2010 May; 95(5):2038-49.
37.
Cagnacci A. , Ferrari S., Tirelli A., et al. Insulin sensitivity and lipid metabolism with oral contraceptives containing chlormadinone acetate or desogestrel: a randomized trial. Contraception.2009;79(2):111-116.
38.
Winkler UH, Sudik R.The effects of two monophasic oral contraceptives containing 30 mcg of ethinyl estradiol and either 2 mg of chlormadinone acetate or 0.15 mg of desogestrel on lipid, hormone and metabolic parameters. Contraception.2009;79(2): 15-23.
39.
Coenen C., Thomas C., Borm G., et al. Comparative evaluation of the androgenecity of four low-dose, fixed combination oral contraceptives. Int J Fertil. 1995;40(suppl 2):92-97.
40.
Nessa A., Latif SA, Uddin M. Effects of low dose oral contraceptives on serum total cholesterol, TAG, HDL-C & LDL-C levels in contraceptive users. Mymensingh Med J. 2005;14(1):26-28.
41.
Kiran G., Kiran H., Ekerbicer HC, Aust NZSerum lipid and lipoprotein changes induced by preparations containing low-dose ethinylestradiol plus levonorgestrel. J Obstet Gynaecol . 2003;43(2):145-147.
42.
Castelli WPThe new pathophysiology of coronary artery disease . Am J Cardiol.1998;82(10B):60t-65t.
43.
Sclavo M.Cardiovascular risk factors and prevention in women: similarities and differences . Ital Heart J. 2001;2(suppl 2): 125-141.
44.
Gruffat D., Durand D., Graulet B., Bauchart D.Regulation of VLDL synthesis and secretion in the liver. Reprod Nutr Dev.1996;36(4):375-389. Review.
45.
Wahl R., Walden C., Knopp R., et al. Effect of estrogen/progestin potency on lipid/lipoprotein cholesterol . N Engl J Med.1993;308(15):862-867.
46.
Walsh BW, Sacks FMEffects of low dose oral contraceptive on very low density lipoprotein metabolism . J. Clin Invest. 1993;91(5):2126-2132.
47.
Sabatini R. , Orsini G., Cagiano R., et al. Noncontraceptive benefits of two combined oral contraceptives with antiandrogenic properties among adolescents. Contraception. 2007;76(5):342-347.
48.
Raudrant D. , Rabe T.Progestogens with antiandrogenic properties . Drug. 2003;63(5):463-492.
49.
Térouanne B., Paris F., Servant N., Georget V., Sultan C.Evidence that chlormadinone acetate exhibits antiandrogenic activity in androgen-dependent cell line. Mol Cell Endocrinol. 2002;198(1-2):143-147.
50.
Lucky AW, Henderson TA, Olson WH, et al. Effectiveness of norgestimate and ethinyl estradiol in treating moderate acne vulgaris. J Am Acad Dermatol.1997;37(5 pt 1): 746-754.
51.
Kageyama Y. , Kitahara S., Tsukamoto T., Tsujii T., Goto S., Oshima H.Chlormadinone acetate as a possible effecrive agent for congenital adrenal hyperplasia to suppress elevated ACTH and antagonize masculinization. Endocr J. 1995;42(4):505-508.
52.
Murakoshi M. , Ikeda R., Fukui N.The effects of chlormadinone acetate (CMA), antiandrogen, on the pituitary, testis, prostate and adrenal gland of the dog with spontaneous benign prostatic hyperplasia. J Toxicol Sci. 2001;26(3):119-127.
